MedTrace Logo

The Use of Mini-dose Glucagon to Prevent Exercise-induced Hypoglycemia in Type 1 Diabetes

NCT02660242 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2020-03-03

Study results available
· View outcomes & findings →

Summary

This project focuses on development of new strategy for the prevention of exercise-associated hypoglycemia using mini-dose glucagon.

Conditions

  • Diabetes Mellitus, Type 1

Interventions

DRUG

G-Pen Mini™ (glucagon injection)

Glucagon (150 µg) 5 minutes before the start of exercise (SQ-abdomen).

OTHER

Glucose Tabs

Dextrose tabs orally (20 grams) 5 minutes before the start of exercise and at 30 minutes of exercise (total 40 grams).

OTHER

Basal Insulin Reduction

Basal insulin reduction to 50% 5 minutes before the start of exercise.

Sponsors & Collaborators

  • Xeris Pharmaceuticals

    collaborator INDUSTRY

  • Jaeb Center for Health Research

    lead OTHER

Principal Investigators

  • Michael Riddell, PhD · York University

  • Michael Rickels, M.D., M.S. · University of Pennsylvania

  • Howard Wolpert, M.D. · Joslin Diabetes Center

  • Stephanie DuBose, M.P.H · Jaeb Center for Health Research

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2017-02-15
Completion
2017-02-15

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02660242 on ClinicalTrials.gov